Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.
Geier A, Rau M, Pathil-Warth A, von der Ohe M, Schattenberg J, Dikopoulos N, Stein K, Serfert Y, Berg T, Buggisch P, Demir M, Roeb E, Wiebner B, Wedemeyer H, Zeuzem S, Hofmann WP. Geier A, et al. Among authors: demir m. Z Gastroenterol. 2023 Jan;61(1):60-70. doi: 10.1055/a-1986-7676. Epub 2023 Jan 9. Z Gastroenterol. 2023. PMID: 36623544 English.
Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, Hüppe D, Teuber G, Wiebner B, Wedemeyer H, Krauth C. Stahmeyer JT, et al. Among authors: demir m. Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1278-85. doi: 10.1097/MEG.0000000000000181. Eur J Gastroenterol Hepatol. 2014. PMID: 25144493
The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
Krawczyk M, Rau M, Grünhage F, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Geier A, Lammert F; NAFLD Clinical Study Group (NAFLD CSG). Krawczyk M, et al. Among authors: demir m. Hepatology. 2017 Aug;66(2):666-667. doi: 10.1002/hep.29100. Epub 2017 Jul 4. Hepatology. 2017. PMID: 28176361 No abstract available.
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Among authors: demir m. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.
Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Demir M, et al. J Gastroenterol Hepatol. 2020 Nov;35(11):1969-1977. doi: 10.1111/jgh.15071. Epub 2020 Apr 30. J Gastroenterol Hepatol. 2020. PMID: 32267559
Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.
Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Lang S, et al. Among authors: demir m. Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0. Sci Rep. 2020. PMID: 32523101 Free PMC article.
1,391 results